Navigation Links
Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement

STOCKHOLM, Sweden, April 21 /PRNewswire-FirstCall/ -- Diamyd Medical AB (publ) has decided on, and successfully executed, a direct placement of in total 991,000 series B shares. The shares have been placed with a limited group of professional investors at a price of 73 SEK per share. The issue raises 72.3 MSEK in total for the Company before issue costs. For each issued and paid new share one warrant is received free of charge, which gives the right to subscribe for a series B share at a price of 100 SEK during April 2009. Full use of the issued warrants will generate an additional 99.1 MSEK in proceeds to the Company.
(Logo: )

(Photo: )

"This issue takes us one further step towards the commercialization of our therapeutic diabetes vaccine Diamyd(R)," says Elisabeth Lindner, President and CEO of Diamyd Medical. "At the same time as resources are secured for financing of the clinical phase III studies which are needed for market approval, we will now continue our partnership discussions for Diamyd(R) and NTDDS from a position of strength. I am warmly welcoming our new shareholders."

Stockholm Corporate Finance has been financial advisor to Diamyd regarding the issue.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1- diabetes and for which Phase III trials have been initiated in both the US and Europe. Furthermore the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site:

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),, Phone: +46-8-661-0026

For pictures and press material, please contact:

Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.),, Phone: +46-8-661-00-26

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diamyd Gets Authorization to Begin Phase III Study in the US
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Strengthens Local Market Candidate Reach Through Acquisition
11. Strengthens Local Market Candidate Reach Through Acquisition
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... recombinant antibodies, today announced that it has received a Phase I Small Business ... by the National Institute of General Medical Sciences (NIGMS), will fund the development ...
(Date:10/13/2015)... , October 13, 2015 ... and development company, has entered into a strategic relationship ... and Paris, France ... --> --> This collaborative arrangement gives ... respected scientific advisory team as well as long established ...
(Date:10/13/2015)... , Oct. 13, 2015  According to Kalorama ... will reach $102 billion by the end of ... the health industry, as it is estimated that ... of laboratory tests. In addition to diagnosing patients, ... evaluate disease progression, monitor drug treatment and conditions, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... of automation systems, material handling solutions and components, is opening its latest Parker ... State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit in ...
Breaking Biology Technology:
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
Breaking Biology News(10 mins):